Preparing an IND Application: CMC
-
Upload
mars-discovery-district -
Category
Business
-
view
17.059 -
download
2
description
Transcript of Preparing an IND Application: CMC
May 2008 P Pekos
Preparing an INDApplication: CMC
Principles & Content OutlinePeter Pekos, President
Dalton Pharma ServicesMay 13, 2008
May 2008 P Pekos
• Integrated synthesis laboratories • Research library • cGMP manufacturing suites • Biopolymer synthesis laboratory • Secure, controlled environment • Analytical laboratory
• over 80 employees
• 42,000 sq ft facility in Greater Toronto Area • Adjacent to Toronto’s York University • Proximity to Toronto area pharma, biotech, medical research facilities
Company Profile
• 26 at Ph.D. / M.Sc. level
May 2008 P Pekos
Services
Contract Research
Custom Synthesis
Contract Analysis
API Manufacturing
Sterile Filling
May 2008 P Pekos
Drug Development Support
Batch Records
AnalyticalSmall Focused LibrariesBulk intermediates & impurity standards
Process Optimization & Scale Up
API Manufacturing (GMP)
• Method Development• Method Validation• Stability Programs• Impurity Identification
Regulatory Support• CMC• IND• NDA
Lead Optimization
SAR elucidation
Prodrug synthesis
Sterile Filling (GMP)
May 2008 P Pekos
Disclaimer
Views presented here are provided toillustrate the general process and issues ofpreparing for an IND
Each therapeutic development program maydiffer in the details particular to that drug
Be sure to consult all laws, regulations andguidances that apply to your situation
May 2008 P Pekos
Business Of MedicalManufacturing
All the issues common to any manufacturingbusiness, plus…• Your product acts DIRECTLY on your consumers• Most products are inherently dangerous• Simple to use and to misuse• Highly intrusive regulatory environment
Conversely, the regulatory environmentprovides for a process to manage businessrisk as well as risk to the public• Consider each Health Authority as a resource to
consult with, not an adversary!
May 2008 P Pekos
Investigational New DrugApplication
IND regulations exempt the investigation of anew drug (or new drug use) from theregulations governing the production andmarketing of a commercial drug product.
Seeks to balance protection of the public withthe need to introduce new therapies.
Current regulations at 21 CFR 312.22 and312.23 contain the general principlesunderlying the IND submission and thegeneral requirements for an IND's contentand format
May 2008 P Pekos
IND regulation of CMC
Balancing protection with investigation leadsto a graduated, “bootstrapping” approach• Early studies provide limited data to assess risk
vs. benefit, consistency and control, etc., sominimize the initial human exposure
• As the program develops, the accuracy, precision,and breadth of your data is expected to improveover time
• By the time of a marketing application, thesponsor must demonstrate they are ready andable to meet the full requirements for a marketeddrug
May 2008 P Pekos
FDA View on Early CMC Data
“It is recognized that modifications to themethod of preparation of the new drugsubstance and dosage form, and evenchanges in the dosage form itself, arelikely as the investigation progresses. Theemphasis in an initial Phase 1 CMCsubmission should, therefore, generally beplaced on providing information that willallow evaluation of the safety of subjectsin the proposed study.”GUIDANCE FOR INDUSTRY. CONTENT AND FORMAT OF INVESTIGATIONALNEW DRUG APPLICATIONS (INDs) FOR PHASE 1 STUDIES OF DRUGS,INCLUDING WELL CHARACTERIZED, THERAPEUTIC, BIOTECHNOLOGY-DERIVED PRODUCTS (Nov 1995)
May 2008 P Pekos
Causes for “Clinical Hold” basedon CMC section of your IND
Unknown or impure components Chemical structures of known or highly likely toxicity Product that cannot remain chemically stable throughout the
testing program proposed Product with an impurity profile indicative of a potential
health hazard or an impurity profile insufficiently defined toassess a potential health hazard
Poorly characterized master or working cell bank Refer to 21 CFR 312.23(a)(7)
(see http://www.fda.gov/cder/guidance/phase1.pdf)
May 2008 P Pekos
Basic CMC Strategy for IND
Develop pre-clinical data or cite research toanswer these two questions:• Does the chemistry of either the drug substance
or the drug product present any signals ofpotential human risk?
• Does the manufacturing of either the drugsubstance or the drug product present any signalsof potential human risk?
Continue to address these questionsthroughout your development program!
May 2008 P Pekos
INTRODUCTION TO cGMP
Legal basis for cGMP What does that “c” mean? General Principles
May 2008 P Pekos
FD & C Act; 501 (a) (2) (B)
“A drug shall be deemed adulterated if:• … the methods used in, or the facilities or
controls used for its manufacture, processing,packing or holding do not conform to or are notoperated or administered in conformity withcurrent good manufacturing practice to assurethat such drug meets the requirements of this Actas to safety and has the identity and strength, andmeets the quality and purity characteristics, whichit purports or is represented to possess.”
May 2008 P Pekos
cGMP Legal Principles
Quality must be built into product• By “taking care” in making medicine• Can’t test quality into product
Missing or inadequate cGMP risk harm• Products(s) may be adulterated (defects need not
be shown before action brought)• Firm is responsible
May 2008 P Pekos
cGMP Legal Principles
Non-compliance may lead to your productfailing to meet your label claims:• Super-potency or sub-potency• Contamination• Misbranding• Bioavailability (e.g., altered pharmacology)• Safety and efficacy
The mere risk of harmful consequencesjustifies legal action and remedy!
May 2008 P Pekos
cGMP Legal Principles
“c” = “Current” = Dynamic• Standards evolve over time, e.g., ICH efforts of
the past decade, and US process overhaulunderway right now**http://www.fda.gov/OHRMS/DOCKETS/98fr/E7-23292.pdf
“Good” Practices• Minimal acceptable standards• Not necessarily “best practices”
• Unless “best” is, in fact, the current minimal
May 2008 P Pekos
cGMP Legal Principles
Feasible and valuable• No “percentage” in practice threshold
• Doesn’t have to be “predominant”• Enforceable even if no one else is currently
practicing it• Although a stronger case is made if someone else
has adopted that practice
May 2008 P Pekos
cGMP Scope
Any ingredient (including excipients) Finished dosage forms administered to
humans and/or animals• OTC, Rx products• Biologics, veterinary drugs• Drugs undergoing study (IND)
Manufacturers, test laboratories, packagers(including pharmacies), and warehouses
May 2008 P Pekos
Excluded from cGMP
Drug products compounded per Section 503Pharmacy Compounding (FDAMA)
Position Emission Tomography (PET)agents, but draft rule published in 2007suggests these will be covered too:• May be met by producing PET drugs in
accordance with the United States Pharmacopeia(USP) general chapter on compounding PETradiopharmaceuticals
May 2008 P Pekos
General cGMP Responsibilities
Prepare, review, approve and distribute SOP Ensure adequate qualifications, training, and
experience for personnel operating under cGMP Follow SOP and MBR Review MBR and executed BR Evaluate all deviations, investigate and resolve
critical deviations Ensure sanitary facilities Calibrate and maintain equipment and facilities, and
document that maintenance Review and approve validation protocols and reports Establish a change control process
May 2008 P Pekos
General Quality Principles
Quality is everyone’s job Sponsors must establish a
quality system Responsibilities must be
clearly stated Real-time quality records Investigate all deviations Quarantine before release
Establish a QualityControl Unit (QCU)• Independent of
production management• Responsible for QC and
QA (QA could be doneseparately)
• Notification process fordefects, recalls,inspections, and seriousGMP deficiencies
May 2008 P Pekos
Quality Control Unit
Must be involved in allquality issues
Must review andapprove all quality-related documents
(See: Quality SystemsRegulation, 21 CFRpart 820)
Cannot delegate mainresponsibilities• Lot release or rejection• Establishing raw
material, WIP, packagingand labeling acceptancesystem
• Batch record review priorto release
• Deviation investigationresolution
• Quality audits andvalidation reviews
• Stability data
May 2008 P Pekos
Content of IND
Item 7: CMC[21 CFR 312.23 (a) (7)]
May 2008 P Pekos
Item 7 of the IND: CMC
7.1 Introduction 7.2 Drug Substance 7.3 Drug Product 7.4 Diluent (if applicable) 7.5 Placebo (if applicable) 7.6 Test Procedures 7.7 Environmental Assessment
May 2008 P Pekos
Introduction: Section 7.1
Drug Substance/Productdescription:• chemical name, structure,
physical, chemical, and/orbiological characteristics,and generic name (ifavailable) and internal IDcode.
Names and amounts ofDrug Substance(s) used inProduct
Names and amounts ofexcipients, includingpreservatives or deliveryenhancers
Container/closuredescription
Diluent used to administerproduct, if applicable
Name, address, anddescription of each locationused in the manufacture ofthe Product andSubstance(s)• Reference existing IND or
DMF if available, if not,provide, floor plans,equipment lists, andmaterial flows for eachlocation
Summary flow chart ofmanufacturing process
May 2008 P Pekos
Drug Substance: Section 7.2
A brief process description:list reagents, solvents, andcatalysts used. A detailedflow diagram isrecommended.
Methods and specs foridentity, strength, quality,and purity• Reference Standard(s)• Brief description of the test
methods• Proposed acceptable limits• Recommend including CofA• Validation data and
established specs may berequested for biotech orhuman/animal source drugs
Full name and streetaddress of eachmanufacturing location
Information on the stabilityof the Drug Substanceduring the tox & clinicalprograms• A brief description of the
stability program and testmethods
• Preliminary tabular databased on representativematerial may be submittedin lieu of final data
• Neither detailed stabilitydata nor the stabilityprotocol should besubmitted
May 2008 P Pekos
Drug Product: Section 7.3
Citing USP-NF may be sufficient List components & quality level
• Active Pharmaceutical Ingredients• Excipients (including alternatives)
• Everything used in themanufacturing process, not justappearing in the final formulation
• For novel excipients, additional infomay be necessary.
• Summary table of composition The full name and street address of
each manufacturing location Brief description of manufacturing and
packaging procedures• Include sterilization process for sterile
products• Flow diagrams are recommended• Specify Container/Closure system
proposed for clinical studies
Methods & specs used for identity, strength,quality, and purity:• Reference Standard(s)• Brief description of methods used• Proposed acceptable limits• Recommend including CofA• Assess bioactivity for biotech drugs• Validation data and established specs may be
requested for biotech or human/animal sourcedrugs.
Information on the stability of the DrugProduct during the tox & clinical programs• A brief description of the stability study and the
test methods in the container/closuresystem and clinical storage conditions
• Preliminary tabular data based onrepresentative material may be submitted.
• Neither detailed stability data nor the stabilityprotocol should be submitted
May 2008 P Pekos
Label information (7.3.9)
A copy of all labels and labelling to be providedto each investigator:
A mock-up or printed representation of theproposed labelling.• Investigational labels in USA must carry a caution
statement as required by 21 CFR 312.6(a).• “Caution: New Drug - Limited by Federal (or United
States) law to investigational use.” NB: Label production and use regulated! NB: Other nations have different rules for labels!
May 2008 P Pekos
Dilulent/PlaceboSections 7.4 & 7.5
A brief general description of thecomposition, manufacture, and control of any• Diluent used to reconstitute the product, if needed• Placebo to be used in the proposed clinical trial(s)
Recommend using diagrammatic and/ortabular information where possible
NB: Placebo lots require the same care asactive lots and consume similar time andresources!
May 2008 P Pekos
Environmental Impact Section
Most investigational drugs able to claimcategorical exclusion from an environmentalassessment under 21 CFR 25.24
Possible exceptions: Cytotoxics or processesthat create large volume of hazardous waste.• See Guidance for Industry for the Submission of
Environmental Assessments for Human DrugApplications and Supplements, November, 1995.
May 2008 P Pekos
Electronic IND Submissions:eCTD format
Differs substantially from paper outlinedescribed here, but same principles apply
Still optional for CDER submissions May offer long term advantages for eventual
marketing applications, but technology andprocess is still evolving
Consult current CDER guidance:http://www.fda.gov/cder/regulatory/ersr/ectd.htm
May 2008 P Pekos
Other CMC Considerations
Investigator’s Brochure references CMC info Integrate the Tox and Clinical protocols with CMC via
the Pharmacy Manual• Storage, handling, and disposal of the drug• If required, preparing/compounding the drug for
administration (e.g., reconstitution with Diluent)• Specifications and stability limits for any contact materials
(e.g., IV bags, catheters, syringes, pumps, etc.)—oftenoverlooked, risking clinical timeline
Combination products (e.g., with device) governedby additional rules, see:http://www.fda.gov/oc/combination/
May 2008 P Pekos
cGMP Resources
Internet WWW site by DMPQ• http://www.fda.gov/cder/dmpq• CGMP regulations and ongoing changes• Division subject contacts• Medical gases• Active pharmaceutical ingredients• Human Drug cGMP Notes• Etc.
May 2008 P Pekos
Other Web Resources
ICH website (future of harmonizedregulation?)• Quality guidelines:• http://www.ich.org/cache/compo/276-254-1.html
CDER handbook (useful background, but notcurrent)• http://www.fda.gov/cder/handbook/
May 2008 P Pekos
Thank you
Special Acknowledgement toMark Winnett